Měnglà virus (MLAV), identified in Rousettus bats, is a phylogenetically distinct member 23 of the family Filoviridae. Because filoviruses Ebola virus (EBOV) and Marburg virus 24 (MARV) modulate host innate immune pathways, MLAV VP35, VP40 and VP24 proteins 25 were compared with their EBOV and MARV homologs for innate immune pathway 26 modulation. In human and Rousettus cells, MLAV VP35 behaved like EBOV and MARV 27 VP35s, inhibiting virus-induced activation of the interferon (IFN)-β promoter. MLAV 28 VP35 inhibited IRF3 phosphorylation and interacted with PACT, a host protein engaged 29 by EBOV VP35 to inhibit RIG-I signaling. MLAV VP35 also inhibited PKR activation. 30 MLAV VP40 was demonstrated to inhibit type I IFN induced gene expression in human 31 and bat cells. It blocked STAT1 tyrosine phosphorylation induced either by type I IFN or 32 over-expressed Jak1, paralleling MARV VP40. MLAV VP40 also inhibited virus-induced 33 IFNβ promoter activation, a property shared by MARV VP40 and EBOV VP24. The 34 inhibition of IFN induction was preserved in the presence of a Jak kinase inhibitor, 35 demonstrating that inhibition of Jak-STAT signaling is not sufficient to explain inhibition 36 of IFNβ promoter activation. MLAV VP24 did not inhibit IFN-induced gene expression or 37 bind karyopherin α5, properties of EBOV VP24. MLAV VP24 also differed from MARV 38 VP24 in that it failed to interact with Keap1 or activate an antioxidant response element 39 reporter gene, due to the absence of a Keap1-binding motif. These studies demonstrate 40 similarities between MLAV and MARV in how they suppress IFN responses and 41 differences in how MLAV VP24 interacts with host pathways. 42 43 53 lacks a Keap1 binding motif and fails to activate this cytoprotective response. These 54 data indicate that MLAV possesses immune suppressing functions that could facilitate 55 human infection. They also demonstrate key differences in MLAV versus either EBOV 56 or MARV engagement of host signaling pathways. 57 58 60 Měnglà virus (MLAV) was discovered when its genomic RNA was identified in the liver 61 of a bat of the Rousettus genus that had been collected in Měnglà County, Yunnan 62 Province, China (1). MLAV has been proposed to represent a new genus, Dianlovirus, 63 within the family Filoviridae. The filovirus family includes three additional genera, 64 Ebolavirus, Marburgvirus and Cuevavirus, that contain viral species isolated from or 65 identified in mammals (2). Placement of MLAV in a distinct genus was based on its 66 comparatively low sequence identity to other filoviruses, phylogenetic and pairwise 67 sequence comparison (PASC) analyses (1). It was also noted to have, compared to 68 other filoviruses, unique gene overlaps and a unique transcription start signal (1). MLAV 69 displays some features more reminiscent of Marburgvirus members than Ebolavirus 70 members. Specifically, MLAV RNA was identified in tissue from a Rousettus bat, the 71 same genus of bat which serves as a MARV reservoir in Africa (3). In addition, the 72 MLAV Large (L) protein exhibits closer phylogenetic relatedness to Marburgvirus L than 73 to the L of other filoviruses, and like Marburgvirus genus members, MLAV lacks signals 74 that direct RNA editing of the Ebolavirus and Cuevavirus glycoprotein (GP) mRNA (4). 75 Filoviruses are noteworthy because of their capacity to cause severe human disease 76 (4). Some members of the Ebolavirus and Marburgvirus genera are zoonotic pathogens 77 that have caused repeated outbreaks with substantial lethality in humans (5). The 78 largest such outbreak on record was caused by Zaire ebolavirus (EBOV) and occurred 79 in West Africa between 2013 and 2016. This resulted in upwards of 28,000 infections, 80 more than 11,000 deaths, and the export of infected cases to the United States and 81 Europe (6). EBOV is also the cause of the second largest filovirus outbreak, which was 82 first recognized in August 2018 and has continued well into 2019 (7).The largest 83 outbreak of MARV occurred in Angola between 2004-2005 and had a reported case 84 fatality rate of 88 percent (5). 85 Likely contributing to the virulence of filoviruses are viral encoded proteins that target 86 host cell innate immune signaling pathways (4). Filovirus VP35 proteins suppress 87 interferon (IFN) α/β responses that play critical roles in innate antiviral immunity (8). 88 VP35 impairment of IFN-α/β production occurs by inhibition of RIG-I-like receptor (RLR) 89 signaling through several mechanisms, including VP35 binding to RLR activating 90 dsRNAs and the interaction of VP35 with PACT, a host protein that facilitates RIG-I 91 activation (9-20). VP35s also inhibit the phosphorylation and activation of the IFN-92 induced kinase PKR (21-24). EBOV VP24, but not MARV VP24, interacts with the NPI-1 93 subfamily of karyopherin alpha (KPNA) (also known as importin alpha) nuclear transport 94 proteins, which includes KPNA1, KPNA5 and KPNA6 (25, 26). The NPI-1 subfamily also 95 mediates nuclear import of STAT1 following its activation by IFN (26-28). The 96 interaction of EBOV VP24 with KPNA competes with tyrosine phosphorylated STAT1 97 (pY-STAT1), blocking pY-STAT1 nuclear import and suppressing expression of IFN 98 stimulated genes (ISGs), a response that mediates the antiviral effects of IFN (25, 26, 99 29, 30). MARV VP40 protein has been demonstrated to suppress IFN-induced signaling 100 and ISG expression, while EBOV VP40 has no known role in IFN antagonism (31). 101 Activation of the Jak family of kinases associated with IFN receptors is inhibited by 102 MARV VP40, blocking phosphorylation and activation of the downstream STAT 103 proteins, including STAT1 (31-33). EBOV VP24 and MARV VP40 have also been 104 described to modestly inhibit IFN-α/β production, although the mechanism(s) are not 105 defined (34, 35). While MARV VP24 does not appear to block IFN responses, it has 106 been demonstrated to interact with Kelch-like ECH-associated protein 1 (Keap1). Under 107 homeostatic conditions, Keap1, a cellular substrate adaptor protein of the Cullin3/Rbx1 108 ubiquitin E3 ligase complex, targets the transcription factor Nuclear factor erythroid 2-109 related factor 2 (Nrf2) for polyubiquitination and proteasomal degradation (36-38). 110 MARV VP24 disrupts the Keap1-Nrf2 interaction, leading to Nrf2-induced expression of 111 genes possessing antioxidant response elements (ARE) (36-38). This activity induces a 112 cytoprotective state that may prolong the life of MARV infected cells. MARV VP24 also 113 relieves Keap1 repression of the NF-κB pathway (39). 114 Given the link between EBOV and MARV innate immune suppressors and virulence, 115 and the unknown potential of MLAV to cause human disease, this study sought to 116 determine whether MLAV possesses effective suppressors of innate immunity. Given 117 the differences in innate immune evasion mechanisms between EBOV and MARV, it 118 was also of interest to determine whether MLAV innate immune evasion mechanisms 119 more closely resemble EBOV or MARV. The data demonstrate that MLAV VP35 120 functions as an IFN antagonist by mechanisms that mirror those of EBOV and MARV 121 VP35. MLAV VP40 is demonstrated to act as a suppressor of IFN-induced signaling, 122 whereas MLAV VP24 does not, mirroring the inhibitory functions of MARV. Both MLAV 123 VP35 and VP40 effectively suppressed IFN responses in human and Rousettus cells. 124 Interestingly, MLAV VP24 does not detectably interact with Keap1 or activate ARE gene 125 expression due to the absence of Keap1-binding sequences found in MARV VP24. 126 Cumulatively, the data demonstrate the presence of IFN evasion functions in MLAV that 127 are effective in human cells, suggesting the virus may have the capacity to cause 128 human disease. The similarities in VP40 immune evasion functions are consistent with 129 a closer genetic relationship of MLAV to MARV than EBOV, but the differences in VP24 130 function are consistent with MLAV occupying a distinct genus within the filovirus family. 131 132 Material and Methods 133 Cells and viruses. HEK293T cells were maintained in Dulbecco's Modified Eagle 134 Medium (DMEM), supplemented with 10% fetal bovine serum (FBS) and cultured at 135 37C and 5% CO 2 . RO6E cells, immortalized fetal cells from Rousettus aegyptiacus, 136 were obtained from BEI Resources and maintained in DMEM F12 and supplemented 137 with 5% FBS. Sendai Virus Cantell (SeV) was grown in 10-day-old embryonating 138 chicken eggs for forty-eight hours at 37C. 139 140 Plasmids. MLAV VP35, VP40, and VP24 coding sequences (based on accession 141 number KX371887) were synthesized by Genscript. The synthesized open reading 142 frames were cloned into a pCAGGS expression vector with a FLAG-tag at the N-143 terminus of each coding sequence. EBOV and MARV viral proteins, GFP-STAT1, HA-144 Jak1, HA-PACT, HA-KPNA5, HA-Keap1 and IRF3 expression plasmids were previously 145 described (8, 13, 25, 31, 36). VP24 K-loop chimeras were made using overlapping PCR. 146 MARV VP24 residues 202-RRIDIEPCCGETVLSESV-219 were inserted into MLAV 147 VP24 between residues 202 and 219 (MLAV VP24 MARV 202-219 ) and the corresponding 148 MLAV residues 202-RAINASGRENESVVQNPI-219 were inserted into MARV VP24 at 149 the same position (MARV VP24 MLAV 202-219 ). 150 Cytokines. Universal type I IFN (UIFN) (PBL) was used at 1000 U/mL in DMEM 151 supplemented with 0.3% FBS for 30 minutes at 37C, unless otherwise stated. 152 Phosphorylation assays. HEK293T cells were transfected using Lipofectamine 2000  153 (Life Technologies). Twenty-four hours post transfection, cells were mock-treated, 154 UIFN-treated or SeV-infected, depending on the assay. Subsequently, cells were lysed 155 in NP40 buffer (50mM Tris-HCl [pH 8.0], 280mM NaCl, 0.5% NP-40) supplemented with 156 cOmplete™ protease inhibitor cocktail (Roche) and PhosSTOP (Roche). Lysates were 157 incubated for ten minutes on ice and clarified for ten minutes at 21,100 x g at 4C. 158 Phosphorylation status of the proteins was determined by western blot. 159 IFN and ISG54-promoter reporter gene assays. HEK293T cells (5x10 4 ) and RO6E 160 cells (2x10 5 ) were co-transfected with 25 ng of an IFN promoter-firefly luciferase 161 reporter plasmid or an interferon stimulated gene 54 (ISG54) promoter-firefly luciferase 162 reporter plasmid, 25 ng of a constitutively expressing Renilla luciferase plasmid (pRLTK, 163 Promega) and the indicated viral protein expression plasmids -HEK293T cells: 62.5, 164 6.25, and 0.625 ng for VP35 and VP40 and 25, 2.5, and 0.25 ng for VP24; RO6E cells: 165 250, 25, and 2.5 ng for EBOV and MARV proteins and 125, 12.5, and 1.25 ng for MLAV 166 proteins. Twenty-four hours post transfection cells were mock-treated, SeV-infected 167 (150 hemagglutinin activity units (HAU)) or UIFN-treated (1000 U/mL). Eighteen hours 168 post-infection or treatment, cells were lysed and analyzed for luciferase activity using a 169 Dual Luciferase  Reporter Assay System (Promega) per the manufacturer's protocol. 170 489 interaction with NPC1 and suppression of IFN responses through several mechanisms 490
Importance 45 EBOV and MARV, members of the family Filoviridae, are highly pathogenic zoonotic 46 viruses that cause severe disease in humans. Both viruses use several mechanisms to modulate the host innate immune response, and these likely contribute to severity of 48 disease. Here, we demonstrate that MLAV, a filovirus newly discovered in a bat, 49 suppresses antiviral type I interferon responses in both human and bat cells. Inhibitory 50 activities are possessed by MLAV VP35 and VP40, which parallels how MARV blocks 51 IFN responses. However, whereas MARV activates cellular antioxidant responses 52 through an interaction between its VP24 protein and host protein Keap1, MLAV VP24
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Firefly luciferase activity was normalized to Renilla luciferase activity. Assays were 171 performed in triplicate; error bars indicate the standard error of the mean (SEM) for the 172 triplicate. Viral protein expression was confirmed by western blot. 173 IFN reporter gene assay in the presence of a Jak1/Jak2 inhibitor. HEK293T cells 174 (5x10 4 ) were co-transfected with 25 ng of an IFN promoter-firefly luciferase reporter 175 plasmid, 25 ng of pRLTK Renilla luciferase reporter plasmid and 62.5, 6.25, and 0.625 176 ng of the indicated viral protein expression plasmids. Twenty-four hours post-177 transfection, cells were pre-treated for one hour with 5M of Ruxolitinib (SelleckChem), 178 a Jak1/Jak2 inhibitor, and then mock-or SeV-infected in the presence of the inhibitor 179 (40) . Eighteen hours post-infection or treatment, cells were lysed and assayed using a 180 dual luciferase assay and analyzed as above. To verify inhibition of Jak1/Jak2 by 181 Ruxolitnib, cells were transfected with 25 ng of an ISG54 promoter-firefly luciferase 182 reporter plasmid and 25 ng of pRLTK reporter plasmid. Twenty-four hours post-183 transfection, cells were pre-treated for one hour with 5M of Ruxolitinib, and then mock-184 or UIFN-treated for eighteen hours in the presence of the inhibitor and assayed for 185 luciferase activity as above.
186 ARE reporter assay. HEK293T cells (5x10 4 ) were co-transfected with an antioxidant 187 response element (ARE) reporter gene, pGL4.37 [luc2P/ARE/Hygro] (Promega) (30 ng) 188 and a pRLTK reporter plasmid (25 ng) along with either empty vector or 62.5, 6.25, 189 and 0.625 ng of EBOV, MARV, MLAV VP24 or chimeric MARV and MLAV expression 190 plasmids. Eighteen hours post-transfection, luciferase activity was assessed and 191 analyzed as above.
Co-immunoprecipitation assays. HEK293T cells were co-transfected with plasmids for FLAG-tagged MLAV proteins, HA-tagged host proteins, and pCAGGS empty vector 194 using Lipofectamine 2000  (LifeTechnologies). Twenty-four hours post-transfection cells 195 were rinsed with PBS and lysed in NP40 buffer supplemented with cOmplete™ 196 protease inhibitor cocktail (Roche). Lysates were clarified by centrifugation and 197 incubated with anti-FLAG M2 magnetic beads (Sigma-Aldrich) for two hours at 4C. 198 Beads were washed 5 times in NP40 buffer and precipitated proteins were eluted by 199 boiling with SDS sample loading buffer or elution with 3X FLAG peptide (Sigma-Aldrich). 200 Whole cell lysates and immunoprecipitated samples were analyzed by western blot. (Figure 1A and 1B) . 238 Expression of EBOV VP24, Lloviu virus (LLOV) VP24 or MARV VP40 has also been 239 reported to impair IFNβ and, in the case of EBOV VP24, IFNλ production (34, 35, 43) . 240 In the present study, in HEK293T cells, modest inhibition of IFNβ promoter activation 241 was evident for EBOV VP24, EBOV VP40, and MARV VP40. MLAV VP40 exhibited 242 potent dose-dependent inhibition of IFNβ promoter activation ( Figure 1A ). Weak, but 243 statistically significant inhibition of IFNβ reporter gene expression was detected for 244 MARV VP24 and MLAV VP24, however, this minimal inhibition may not be biologically 245 relevant. In RO6E cells, MLAV VP40 inhibition of IFNβ promoter activation was also 246 detected but only at the highest concentration of transfected plasmid ( Figure 1B) . 247 EBOV and MARV VP35 inhibition of RLR signaling pathways results in inhibition of the 248 phosphorylation and activation of transcription factor interferon regulatory factor 3 249 (IRF3) (9, 44, 45) . In order to determine whether MLAV VP35 can inhibit activation of 250 IRF3, HEK293T cells were co-transfected with either empty vector or an IRF3 251 expression plasmid and plasmids that express FLAG-tagged EBOV, MARV, and MLAV 252 VP35 ( Figure 1C ). Twenty-four hours post-transfection, cells were either mock-or SeV- EBOV and MARV VP35 interact with host protein PACT, and this interaction contributes 260 to VP35 inhibition of 23) . To determine if MLAV VP35 suppresses 261 IFN production through a similar mechanism, the PACT-VP35 interactions were 262 evaluated by co-immunoprecipitation assay ( Figure 1D ). FLAG-tagged EBOV, MARV, 263 and MLAV VP35 or empty vector expression plasmids were co-transfected with HA-264 tagged PACT in HEK293T cells. A VP35 dsRNA binding mutant (VP35 KRA ) that has 265 previously been previously shown to lack the ability to interact with PACT was included 266 as a negative control(13). All three wildtype VP35 proteins were demonstrated to 267 interact with PACT, with MLAV VP35 interacting comparably to EBOV VP35. Together, phosphorylation to a similar degree as MARV VP40. MLAV VP24 did not detectably 302 affect STAT1 phosphorylation. 303 MARV VP40 inhibits STAT1 phosphorylation following over-expression of Jak1(31). To 304 determine whether MLAV VP40 can prevent Jak1 induced STAT1 phosphorylation, HA-tagged Jak1 was co-transfected with empty vector or FLAG-tagged EBOV, MARV or 306 MLAV VP40. As expected, expression of exogenous Jak1 induced STAT1 tyrosine 307 phosphorylation, and this was suppressed in the presence of MARV VP40 ( Figure 4C ). 308 Similarly, MLAV VP40 prevented Jak1-dependent STAT1 phosphorylation, suggesting 309 that MLAV VP40 inhibits IFN signaling through the same mechanism used by MARV 310 VP40. 311 EBOV VP24 interacts with NPI-1 subfamily members of the KPNA nuclear transporters, 312 including KPNA5, to block nuclear import of pY-STAT1(26-28). To assess whether 313 MLAV VP24 interacts with KPNA5, co-immunoprecipitation assays were performed in 314 HEK293T cells ( Figure 4D ). KPNA5 did not precipitate in the absence of a co- The reverse chimera was also generated, with MLAV sequences replacing the K-loop in 363 MARV VP24 (MARV VP24 MLAV 202-219 ) ( Figure 8A ). Transferring the MARV K-loop 364 sequence to MLAV VP24 conferred the capacity to activate an ARE response while 365 transfer of the MLAV sequence to MARV VP24 abolished the activation ( Figure 8B ). 366 Interaction with human Keap1 ( Figure 8C ) and bat Keap1 ( Figure 8D ) yielded 367 corresponding data where interaction was dependent on the MARV VP24 K loop. 368 Collectively, these data demonstrate that the lack of ARE gene expression by MLAV 369 VP24 is due to the lack of a Keap1 binding motif.
370

Discussion
371
The data in this study provide functional evidence that MLAV is biologically distinct from 372 other filoviruses and support its classification in its own genus. The placement of MLAV 373 in a distinct genus was based on its relatively low sequence identity to other filoviruses(1). It was also noted to have, compared to other filoviruses, unique gene (9, 10, 12-14, 16, 19, 20, 45) . This may reflect binding and sequestration of RIG-I activating dsRNAs (13, 20) . The VP35 dsRNA binding domain, also known as the 398 interferon inhibitory domain (IID), directly contacts the phosphodiester backbone of 399 dsRNA, via residues that comprise a central basic patch, to mediate this interaction (10-400 12, 17, 18, 45) . EBOV VP35 also caps the ends of dsRNA in a manner that likely masks 401 5'-triphosphates, which contribute to recognition of RNAs by 17) . VP35 402 interaction with host protein PACT, which interacts with and facilitates activation of RIG-403 I, also contributes to inhibition (13, 55) . Because the residues that make up the central 404 basic patch are conserved between MLAV and other filoviral VP35s (1), MLAV is likely 405 to bind to dsRNA. Given that it also interacts with PACT ( Figure 1D ), its mechanisms of 406 inhibition are likely very similar to other filoviral VP35s. 407 EBOV, MARV and LLOV VP35 have also been demonstrated to inhibit activation of 408 PKR, an IFN-induced, dsRNA-activated protein kinase that exerts antiviral effects by 409 suppressing translation (21-24, 43). The mechanism by which VP35s inhibit PKR 410 remains ambiguous, however, mutation of multiple central basic patch residues in 411 EBOV or MARV VP35 disrupts the inhibitory activity (22, 23) . In contrast, single point 412 mutations that disrupt EBOV VP35 dsRNA binding activity leave PKR inhibition intact, 413 suggesting that inhibition of PKR is not dependent upon VP35-dsRNA interaction or 414 sequestration (21, 22) . Consistent with PKR inhibition being an important function for 415 filoviruses, this activity is conserved in MLAV as well. 416 The IFN-inhibitory activities of both EBOV and MARV VP35 have been demonstrated to 417 be important for efficient virus replication in 44) . In 418 addition to blocking the production of antiviral IFNs, VP35 inhibition of RIG-I also 419 suppresses maturation of dendritic cells when expressed alone or in the context of EBOV infection (15, 56, 57) . This activity impairs adaptive immunity to EBOV (58, 59) . 421 Therefore, VP35 likely inhibits adaptive, as well as innate, antiviral defenses. Disruption EBOV and LLOV VP24 targets KPNA proteins in a manner that prevents pY-STAT1 456 nuclear transport, inhibiting ISG expression (25, 26, 29, 30, 43) . 457 Given that MLAV VP40 mirrored MARV VP40 in its inhibition of the IFN response, it was 458 of interest to determine whether MLAV VP24 would similarly mimic MARV VP24 in 459 terms of interaction with host signaling pathways. However, MLAV VP24 lacks a 460 sequence that resembles the MARV VP24 K-loop and, correspondingly, did not interact 461 with human or a bat-derived Keap1 and did not activate an ARE promoter. Chimeric 462 MARV-MLAV VP24 proteins confirmed that the absence of the K-loop sequence can 463 explain the lack of MLAV VP24 effects on antioxidant responses. Furthermore, 464 consistent with the absence of MLAV VP24 inhibitory activity in IFN-signaling assays, it also fails to interact with KPNA5. The interface between EBOV VP24 and KPNA covers 466 a large surface area and involves multiple points of contact (30). This precluded the 467 mapping of specific amino acid residues that explain the lack of MLAV VP24-KPNA5 468 interaction. Nonetheless, these data presented here indicate that MLAV VP24 does not 469 reflect the functions of either MARV or EBOV VP24. It will be of interest to determine 470 whether MLAV VP24 engages different host pathway(s). 471 The inhibition of IFNβ promoter activity by MLAV VP40 parallels the inhibition by EBOV 472 VP24 and MARV VP40, although inhibition by MLAV VP40 appeared to be more potent. 473 MARV VP40 and EBOV VP24 inhibition of IFN-α/β production and, in the case of EBOV 474 VP24, production of IFN-λ as well, have been previously reported (34, 35) . However, 475 the mechanism(s) for these inhibitory activities are incompletely defined, although 476 EBOV VP24 was implicated as having an effect post-IRF3 phosphorylation (34). additional mechanism acting on the production side. Upon treatment of cells with a 483 Jak1/Jak2 inhibitor, which removes any potential contribution of IFN signaling inhibition, 484 MLAV VP40 maintained inhibition of the IFN promoter. This suggests MLAV VP40 has 485 an additional mechanism(s) of IFN antagonism that requires further exploration. 486 Cumulatively, the present study has identified several functions of MLAV proteins that, 487 in conjunction with previously published data, indicate a compatibility with infection of humans. These include the capacity of MLAV GP to mediate entry into human cells via 24. 
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